CELCUITY INC (CELC) Fundamental Analysis & Valuation

NASDAQ:CELC • US15102K1007

Current stock price

106.04 USD
-6.95 (-6.15%)
At close:
106.04 USD
0 (0%)
After Hours:

This CELC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CELC Profitability Analysis

1.1 Basic Checks

  • In the past year CELC has reported negative net income.
  • CELC had a negative operating cash flow in the past year.
  • In the past 5 years CELC always reported negative net income.
  • In the past 5 years CELC always reported negative operating cash flow.
CELC Yearly Net Income VS EBIT VS OCF VS FCFCELC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of CELC (-34.19%) is better than 62.09% of its industry peers.
  • CELC has a Return On Equity of -139.12%. This is in the lower half of the industry: CELC underperforms 61.70% of its industry peers.
Industry RankSector Rank
ROA -34.19%
ROE -139.12%
ROIC N/A
ROA(3y)-33.98%
ROA(5y)-41.85%
ROE(3y)-57.49%
ROE(5y)-59.3%
ROIC(3y)N/A
ROIC(5y)N/A
CELC Yearly ROA, ROE, ROICCELC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • CELC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CELC Yearly Profit, Operating, Gross MarginsCELC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

5

2. CELC Health Analysis

2.1 Basic Checks

  • CELC has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for CELC has been increased compared to 5 years ago.
  • CELC has a worse debt/assets ratio than last year.
CELC Yearly Shares OutstandingCELC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
CELC Yearly Total Debt VS Total AssetsCELC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • An Altman-Z score of 7.56 indicates that CELC is not in any danger for bankruptcy at the moment.
  • CELC has a better Altman-Z score (7.56) than 79.30% of its industry peers.
  • CELC has a Debt/Equity ratio of 2.74. This is a high value indicating a heavy dependency on external financing.
  • CELC has a worse Debt to Equity ratio (2.74) than 80.46% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.74
Debt/FCF N/A
Altman-Z 7.56
ROIC/WACCN/A
WACCN/A
CELC Yearly LT Debt VS Equity VS FCFCELC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • CELC has a Current Ratio of 12.26. This indicates that CELC is financially healthy and has no problem in meeting its short term obligations.
  • CELC's Current ratio of 12.26 is amongst the best of the industry. CELC outperforms 86.27% of its industry peers.
  • A Quick Ratio of 12.26 indicates that CELC has no problem at all paying its short term obligations.
  • CELC has a Quick ratio of 12.26. This is amongst the best in the industry. CELC outperforms 86.27% of its industry peers.
Industry RankSector Rank
Current Ratio 12.26
Quick Ratio 12.26
CELC Yearly Current Assets VS Current LiabilitesCELC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

1

3. CELC Growth Analysis

3.1 Past

  • CELC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -40.61%.
EPS 1Y (TTM)-40.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 39.87% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-35.7%
EPS Next 2Y-21.7%
EPS Next 3Y16.29%
EPS Next 5Y39.87%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CELC Yearly Revenue VS EstimatesCELC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
CELC Yearly EPS VS EstimatesCELC Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

0

4. CELC Valuation Analysis

4.1 Price/Earnings Ratio

  • CELC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CELC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CELC Price Earnings VS Forward Price EarningsCELC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CELC Per share dataCELC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • CELC's earnings are expected to grow with 16.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.7%
EPS Next 3Y16.29%

0

5. CELC Dividend Analysis

5.1 Amount

  • No dividends for CELC!.
Industry RankSector Rank
Dividend Yield 0%

CELC Fundamentals: All Metrics, Ratios and Statistics

CELCUITY INC

NASDAQ:CELC (3/20/2026, 8:00:00 PM)

After market: 106.04 0 (0%)

106.04

-6.95 (-6.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-25
Inst Owners96.45%
Inst Owner Change19.48%
Ins Owners10.28%
Ins Owner Change0.02%
Market Cap4.91B
Revenue(TTM)N/A
Net Income(TTM)-162.72M
Analysts85.88
Price Target115.26 (8.69%)
Short Float %23.94%
Short Ratio12.88
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.36%
Min EPS beat(2)-15.3%
Max EPS beat(2)10.59%
EPS beat(4)2
Avg EPS beat(4)-5.04%
Min EPS beat(4)-17.61%
Max EPS beat(4)10.59%
EPS beat(8)5
Avg EPS beat(8)1.13%
EPS beat(12)5
Avg EPS beat(12)-6.44%
EPS beat(16)5
Avg EPS beat(16)-9.26%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.26%
PT rev (3m)6.16%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.87%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.12%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 41.95
P/tB 41.95
EV/EBITDA N/A
EPS(TTM)-3.67
EYN/A
EPS(NY)-4.16
Fwd EYN/A
FCF(TTM)-3.12
FCFYN/A
OCF(TTM)-3.12
OCFYN/A
SpS0
BVpS2.53
TBVpS2.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -34.19%
ROE -139.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.98%
ROA(5y)-41.85%
ROE(3y)-57.49%
ROE(5y)-59.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 2.74
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 155.63%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.26
Quick Ratio 12.26
Altman-Z 7.56
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)112.26%
Cap/Depr(5y)77.3%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-40.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.43%
EPS Next Y-35.7%
EPS Next 2Y-21.7%
EPS Next 3Y16.29%
EPS Next 5Y39.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-65.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-55.17%
EBIT Next 3Y5.75%
EBIT Next 5YN/A
FCF growth 1Y-221.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-222.49%
OCF growth 3YN/A
OCF growth 5YN/A

CELCUITY INC / CELC Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CELCUITY INC (CELC) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CELC.


Can you provide the valuation status for CELCUITY INC?

ChartMill assigns a valuation rating of 0 / 10 to CELCUITY INC (CELC). This can be considered as Overvalued.


Can you provide the profitability details for CELCUITY INC?

CELCUITY INC (CELC) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for CELC stock?

The Earnings per Share (EPS) of CELCUITY INC (CELC) is expected to decline by -35.7% in the next year.